Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study

Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R. and Chaouche-Teyara, K. (2019) Secukinumab for moderate to severe palmoplantar pustular psoriasis: Results of the 2PRECISE study. Journal of the American Academy of Dermatology, 80(5), pp. 1344-1352. (doi: 10.1016/j.jaad.2019.01.066) (PMID:30716404)

[img]
Preview
Text
180245.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

852kB

Abstract

Palmoplantar pustular psoriasis (PPP) is a debilitating disease of the palms and/or soles that is resistant to treatment. Secukinumab, an anti-IL-17A monoclonal antibody, is highly efficacious in the treatment of moderate to severe psoriasis. The primary objective was ppPASI75 response with secukinumab at Week 16 vs. placebo (2.5% significance level). 2PRECISE was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing secukinumab 300 mg (n=79) and 150 mg (n=80) to placebo (n=78) in subjects with moderate to severe PPP over 52 Weeks. The primary endpoint was not met. At Week 16, 26.6% of subjects with secukinumab 300 mg achieved ppPASI75 vs.. 14.1% with placebo (P=0.0411) [OR: 2.62; 95% CI: 1.04, 6.60]. At Week 52, 41.8% of subjects with secukinumab 300mg had ppPASI75. More DLQI 0/1 responses were achieved with secukinumab 300 mg (13.0%) vs. placebo (4.3%) at Week 16. At Week 52, 43.1% of subjects receiving secukinumab 300 mg had DLQI 0/1. No unexpected adverse events were observed. Small sample size and characteristics of PPP disease course. PPP patients treated with secukinumab 300 mg showed benefit in ppPASI75 responses over 52 weeks and improved quality of life. [Abstract copyright: Copyright © 2019. Published by Elsevier Inc.]

Item Type:Articles
Keywords:Palmoplantar pustular psoriasis, ppPASI75, quality of life, randomized controlled trial, secukinumab.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Burden, Professor David
Authors: Mrowietz, U., Bachelez, H., Burden, A. D., Rissler, M., Sieder, C., Orsenigo, R., and Chaouche-Teyara, K.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Journal of the American Academy of Dermatology
Publisher:Elsevier
ISSN:0190-9622
ISSN (Online):1097-6787
Published Online:01 February 2019
Copyright Holders:Copyright © 2019 by the American Academy of Dermatology
First Published:First published in Journal of the American Academy of Dermatology 80(5):1344–1352
Publisher Policy:Reproduced under a Creative Commons Licence

University Staff: Request a correction | Enlighten Editors: Update this record